Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure

Simultaneous neprilysin inhibition (NEPi) and angiotensin receptor blockade (ARB) with sacubitril/valsartan improves cardiac function and exercise tolerance in patients with heart failure. However, it is not known whether these therapeutic benefits are primarily due to NEPi with sacubitril or ARB wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of physiology. Heart and circulatory physiology 2019-02, Vol.316 (2), p.H289-H297
Hauptverfasser:	Maslov, Mikhail Y, Foianini, Stephan, Mayer, Dita, Orlov, Michael V, Lovich, Mark A
Format:	Artikel
Sprache:	eng
Schlagworte:	Aminobutyrates - pharmacology Aminobutyrates - therapeutic use Angiotensin Angiotensin Receptor Antagonists - pharmacology Angiotensin Receptor Antagonists - therapeutic use Animals Aortic valve Blood pressure Collagen Congestive heart failure Drug Combinations Drug Synergism Exercise Tolerance Fibrosis Heart Heart - drug effects Heart failure Heart Failure - drug therapy Heart Failure - pathology Heart Failure - physiopathology Hemodynamics Hospitalization Male Muscle contraction Myocardial Contraction Neprilysin Rats Rats, Sprague-Dawley Systolic pressure Tetrazoles - pharmacology Tetrazoles - therapeutic use Therapy Valsartan - pharmacology Valsartan - therapeutic use Ventricle
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!